If the drug is eventually approved, Comp360 will be a welcome addition to the treatment options for serious depression.

A depression drug candidate that’s a key part of Johnson & Johnson’s neuroscience strategy has failed a Phase 3 clinical trial, the latest dose of disappointing news for an emerging class of medicines ...